Literature DB >> 1463094

Well-differentiated thymic carcinoma. An organotypical low-grade carcinoma with relationship to cortical thymoma.

T Kirchner1, B Schalke, J Buchwald, M Ritter, A Marx, H K Müller-Hermelink.   

Abstract

Based on a study of 26 cases, the well-differentiated thymic carcinoma is described as a distinct organotypical carcinoma of the thymus with low-grade malignancy. It is characterized by a predominance of epithelial cells with usually low mitotic rate, an epidermoid differentiation with slight to moderate cytological atypia, the constant presence of interepithelial immature cortical thymocytes, lobular growth, and formation of epithelial palisades around perivascular spaces. The tumor occurs at age 14 to 76 years in both sexes. An association with myasthenia gravis is found in 77% of the patients, and 83% of the tumors show invasion of adjacent organs or endothoracic metastasis at primary operation. This rate is higher than in cortical thymomas (47%) but lower than in other thymic carcinomas (92%). Two of 18 patients with follow-up died of tumor recurrence and pleural metastasis. Well-differentiated thymic carcinoma can be related to cortical thymoma by common morphological features and a similar immunophenotype of epithelial cells. It must be differentiated from the lymphocyte-depleted cortical thymomas after corticosteroid treatment and from the benign epithelial-rich medullary thymomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463094

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  25 in total

1.  Pathologic Finding of Thymic Carcinoma Accompanied by Myasthenia Gravis.

Authors:  Se Hoon Kim; Im Suk Koh; Yang Ki Minn
Journal:  J Clin Neurol       Date:  2015-08-21       Impact factor: 3.077

2.  MR imaging of thymic epithelial tumors: correlation with World Health Organization classification.

Authors:  Atsuo Inoue; Noriyuki Tomiyama; Kiminori Fujimoto; Junko Sadohara; Itsuko Nakamichi; Yasuhiko Tomita; Katsuyuki Aozasa; Mitsuko Tsubamoto; Sachiko Murai; Javzandulam Natsag; Hiromitsu Sumikawa; Naoki Mihara; Osamu Honda; Seiki Hamada; Takeshi Johkoh; Hironobu Nakamura
Journal:  Radiat Med       Date:  2006-04

3.  Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Authors:  Priska Leisibach; Didier Schneiter; Alex Soltermann; Yoshi Yamada; Walter Weder; Wolfgang Jungraithmayr
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 4.  Thymoma and thymic carcinoma: an update of the WHO Classification 2004.

Authors:  Philipp Ströbel; Alexander Marx; Andreas Zettl; Hans Konrad Müller-Hermelink
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Thymic epithelial tumors can develop along two different pathogenetic pathways.

Authors:  R Zhou; A Zettl; P Ströbel; K Wagner; H K Müller-Hermelink; S Zhang; A Marx; P Starostik
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  AB thymoma with atypical type A component with delayed multiple lung and brain metastases.

Authors:  Wieslawa Grajkowska; Ewa Matyja; Jacek Kunicki; Sylwia Szymanska; Alexander Marx; Cleo-Aron Weis; Renata Langfort; Malgorzata Szolkowska
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 7.  Thymic neoplasms: a clinical update.

Authors:  Mark Mikhail; Yasmin Mekhail; Tarek Mekhail
Journal:  Curr Oncol Rep       Date:  2012-08       Impact factor: 5.075

8.  Recurrent thymoma: radiological (CT and FDG-PET) and histological (WHO criteria) features.

Authors:  Hisao Ito; Kazuyoshi Shimada; Katsuhiko Isogami; Takashi Kondo; Tomohiro Kaneta; Shoki Takahashi; Hiroshi Fukuda
Journal:  Radiat Med       Date:  2006-05

9.  Type AB thymoma is not a mixed tumor of type A and type B thymomas, but a distinct type of thymoma.

Authors:  Yukari Miki; Kana Hamada; Tadashi Yoshino; Katsuya Miyatani; Kiyoshi Takahashi
Journal:  Virchows Arch       Date:  2014-05-07       Impact factor: 4.064

10.  Neoplastic thymic epithelial cells of human thymoma support T cell development from CD4-CD8- cells to CD4+CD8+ cells in vitro.

Authors:  M Inoue; Y Fujii; M Okumura; Y Takeuchi; H Shiono; S Miyoshi; H Matsuda; R Shirakura
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.